TRAASER

One line pitch:
Traaser develops a software, Diagen, an expert system to help doctors understand the genome of their patient and provide a personalized, health care.

Market Analysis:
Traaser responds to a strong demand of the market and starts its activities at the better moment: On one side, Next Generation Sequencing brings the routine use of sequencing in clinics and on the other side, clinicians demonstrate the medical interest of genomics-based diagnostic. Positionned on a market evaluated to $1B, with a CAGR of 22%, recent massive investment of different countries in genomics is opening huge opportunities for development of bioinformatics. In France, Traaser will benefit directly from the plan de médecine génomique 2025 which will provide more than 200.000 clinical whole genome sequences a year.

Value proposition:
Diagen, expert system, provides automatic analysis of genome in clinical context. The unique algorithms of Diagen provide precise results in short time, compatible with application of genomics in clinical activities. Automatic analysis limits time-consuming, tedious and error-prone manual operations. Precise: Diagen delivers only pertinent and actionable data to clinicians. Versatile: Setting-up an analyses has never been so easy, independently of sequencing technology, IT infrastructure, or medical specialty. Scalable: Diagen scales up easily with the diagnostic volume required by personalized medicine. More, the collaborative capacity of Diagen allows to increase diagnostic capacity.

Business Model:
Traaser is selling Diagen to laboratories providing genetic diagnostic services, based on NGS technology. Laboratories can be public laboratories in hospital, or private laboratories. The solution can be provided by two distribution modes : A SAAS model (Software As A Service) or by delivering a pre-configured server directly to the client. Laboratories are charged for the access to the system, than it is charged for each use of the software. The market of diagnostic is oligopolistic with a few numbers of actors. Hence, commercial prospection is in a first instance realized by the founders of the company.

IP and Regulatory situation:
Software developments are the property of Traaser and protected by the secret. In collaboration with clinical partners, we are developing specific medical databases.